Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael J Schell

Showing results (91-100 of 156) with videos related to

Pageof 16
Sort By:
British Journal of Cancer|April 8, 2021
A phase 1/2 trial of ibrutinib in combination with pembrolizumab in patients with mismatch repair proficient metastatic colorectal cancerDae Won Kim, Elaine Tan, Jun-Min Zhou, et al.
Blood|August 19, 2006
ABCG2 expression, function, and promoter methylation in human multiple myelomaJoel G Turner, Jana L Gump, Chunchun Zhang, et al.
Glia|June 15, 2010
Phosphorylation status of pyruvate dehydrogenase distinguishes metabolic phenotypes of cultured rat brain astrocytes and neuronsNader D Halim, Thomas Mcfate, Ahmed Mohyeldin, et al.
Clinical Genitourinary Cancer|March 7, 2022
Coordinated Pembrolizumab and High Dose IL-2 (5-in-a-Row Schedule) for Therapy of Metastatic Clear Cell Renal CancerJonathan Chatzkel, Michael J Schell, Jad Chahoud, et al.
International Journal of Cancer|December 15, 2010
Phase II study of sunitinib malate, a multitargeted tyrosine kinase inhibitor in patients with relapsed or refractory soft tissue sarcomas. Focus on three prevalent histologies: leiomyosarcoma, liposarcoma and malignant fibrous histiocytomaS Tariq Mahmood, Samuel Agresta, Carlos E Vigil, et al.
Scientific Reports|October 26, 2012
12-Chemokine gene signature identifies lymph node-like structures in melanoma: potential for patient selection for immunotherapy?Jane L Messina, David A Fenstermacher, Steven Eschrich, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 2002
Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage IIIB/IV non-small-cell lung cancerMark A Socinski, Michael J Schell, Amy Peterman, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|September 3, 2013
Phase II trial of a GM-CSF-producing and CD40L-expressing bystander cell line combined with an allogeneic tumor cell-based vaccine for refractory lung adenocarcinomaBen C Creelan, Scott Antonia, David Noyes, et al.
Cancer|February 27, 2008
Phase 2 trial of docetaxel and gefitinib in the first-line treatment of patients with advanced nonsmall-cell lung cancer (NSCLC) who are 70 years of age or olderGeorge R Simon, Martine Extermann, Alberto Chiappori, et al.
The American Journal of Pathology|January 13, 2011
ERCC1 and RRM1 in the international adjuvant lung trial by automated quantitative in situ analysisGerold Bepler, Ken André Olaussen, Anne-Lise Vataire, et al.
Pageof 16

Showing results (91-100 of 156) with videos related to

Sort By:
Pageof 16
British Journal of Cancer|April 8, 2021
A phase 1/2 trial of ibrutinib in combination with pembrolizumab in patients with mismatch repair proficient metastatic colorectal cancerDae Won Kim, Elaine Tan, Jun-Min Zhou, et al.
Blood|August 19, 2006
ABCG2 expression, function, and promoter methylation in human multiple myelomaJoel G Turner, Jana L Gump, Chunchun Zhang, et al.
Glia|June 15, 2010
Phosphorylation status of pyruvate dehydrogenase distinguishes metabolic phenotypes of cultured rat brain astrocytes and neuronsNader D Halim, Thomas Mcfate, Ahmed Mohyeldin, et al.
Clinical Genitourinary Cancer|March 7, 2022
Coordinated Pembrolizumab and High Dose IL-2 (5-in-a-Row Schedule) for Therapy of Metastatic Clear Cell Renal CancerJonathan Chatzkel, Michael J Schell, Jad Chahoud, et al.
International Journal of Cancer|December 15, 2010
Phase II study of sunitinib malate, a multitargeted tyrosine kinase inhibitor in patients with relapsed or refractory soft tissue sarcomas. Focus on three prevalent histologies: leiomyosarcoma, liposarcoma and malignant fibrous histiocytomaS Tariq Mahmood, Samuel Agresta, Carlos E Vigil, et al.
Scientific Reports|October 26, 2012
12-Chemokine gene signature identifies lymph node-like structures in melanoma: potential for patient selection for immunotherapy?Jane L Messina, David A Fenstermacher, Steven Eschrich, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 2002
Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage IIIB/IV non-small-cell lung cancerMark A Socinski, Michael J Schell, Amy Peterman, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|September 3, 2013
Phase II trial of a GM-CSF-producing and CD40L-expressing bystander cell line combined with an allogeneic tumor cell-based vaccine for refractory lung adenocarcinomaBen C Creelan, Scott Antonia, David Noyes, et al.
Cancer|February 27, 2008
Phase 2 trial of docetaxel and gefitinib in the first-line treatment of patients with advanced nonsmall-cell lung cancer (NSCLC) who are 70 years of age or olderGeorge R Simon, Martine Extermann, Alberto Chiappori, et al.
The American Journal of Pathology|January 13, 2011
ERCC1 and RRM1 in the international adjuvant lung trial by automated quantitative in situ analysisGerold Bepler, Ken André Olaussen, Anne-Lise Vataire, et al.
Pageof 16